Skip to main content
. 2022 Jun 9;13:868809. doi: 10.3389/fimmu.2022.868809

Figure 2.

Figure 2

Area under the receiver operating characteristics curves (AUROC) for predicting Progressive Diseases (PD) after therapy with anti–programmed cell death protein 1 (PD-1) plus lenvatinib using baseline liver stiffness (LS) values of tumorous foci. (A) The training set (n = 93) and (B) the validation set (n = 40).